SULFADIAZINE
(sul-fa-dye'a-zeen)
Microsulfon
Classifications: antiinfective; sulfonamide antibiotic
Prototype: Sulfisoxazole
Pregnancy Category: B
|
500 mg tablets
Short-acting sulfonamide, slightly less soluble than sulfisoxazole. Exerts bacteriostatic effect by interfering with bacterial
utilization of PABA, thereby inhibiting folic acid biosynthesis required for bacterial growth.
Effective against a wide range of gram-positive and gram-negative microorganisms.
Used in combination with pyrimethamine for treatment of cerebral toxoplasmosis and chloroquine-resistant malaria.
Hypersensitivity to sulfonamides or to any ingredients in the formulation; pregnancy (category C).
Application of lotion to denuded or debrided skin; lactation.
Mild to Moderate Infections
Adult: PO Loading Dose 2–4 g loading dose PO Maintenance Dose 2–4 g/d in 4–6 divided doses
Child: PO Loading Dose
>2 mo, 75 mg/kg PO Maintenance Dose 150 mg/kg/d in 4–6 divided doses (max: 6 g/d)
Rheumatic Fever Prophylaxis
Adult: PO
<30 kg, 500 mg/d; >30 kg, 1 g/d
Toxoplasmosis
Adult: PO 2–8 g/d divided q6h
Child: PO
>2 mo, 100–200 mg/kg/d divided q6h
Neonate: PO 50 mg/kg q12h times 12 mo
|
Oral
- Maintain sufficient fluid intake to produce urinary output of at least 1500 mL/24 h for children between 3000 and 4000 mL/24
h for adults. Concomitant administration of urinary alkalinizer may be prescribed to reduce possibility of crystalluria and
stone formation.
- Store in tight, light-resistant containers.
CNS: Headache, peripheral neuritis, peripheral neuropathy, tinnitus, hearing loss, vertigo, insomnia, drowsiness, mental depression,
acute psychosis, ataxia, convulsions, kernicterus (newborns). GI:
Nausea, vomiting, diarrhea, abdominal pains, hepatitis, jaundice, pancreatitis, stomatitis. Hematologic: Acute hemolytic anemia (especially in patients with G6PD deficiency), aplastic anemia, methemoglobinemia, agranulocytosis, thrombocytopenia, leukopenia, eosinophilia, hypoprothrombinemia. Body as a Whole: Headache, fever, chills, arthralgia, malaise, allergic myocarditis, serum sickness, anaphylactoid reactions, lymphadenopathy, local reaction following IM injection, fixed drug eruptions, diuresis, overgrowth of nonsusceptible organisms,
LE phenomenon. Skin: Pruritus, urticaria, rash, erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis, alopecia, photosensitivity, vascular lesions. Urogenital:
Crystalluria, hematuria, proteinuria, anuria, toxic nephrosis, reduction in sperm count. Metabolic: Goiter, hypoglycemia. Special Senses: Conjunctivitis, conjunctival or scleral infection, retardation of corneal healing (ophthalmic ointment).
Drug:
paba-containing local anesthetics may antagonize sulfa's effects; oral anticoagulants potentiate hypoprothrombinemia; may potentiate sulfonylurea-induced hypoglycemia. May decrease concentrations of cyclosporine; may increase levels of phenytoin.
Absorption: Readily absorbed from GI tract. Peak: 3–6 h. Distribution: Distributed to most tissues, including CSF; crosses placenta. Metabolism: Metabolized in liver. Elimination: Excreted in urine.
Assessment & Drug Effects
- Lab tests: Baseline and periodic urine C&S to determine drug effectiveness; with long-term therapy, CBC, Hct and Hgb.
- Monitor hydration status.
Patient & Family Education
- Take drug exactly as prescribed. Do not alter schedule or dose; take total amount prescribed unless physician changes the
regimen.
- Drink fluids liberally unless otherwise directed.
- Report early signs of blood dyscrasias (sore throat, pallor, fever) promptly to the physician.
- Do not breast feed while taking this drug without consulting physician.
1%)
Canadian drug name; 
Prototype drug